Stay updated on LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.

Latest updates to the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous funding-status notice (v3.4.1) as part of the site update. These updates do not alter the trial information or how users access it.SummaryDifference0.4%

- Check41 days agoChange DetectedThe update introduces a site-wide funding notice and a new site version (v3.4.1), replacing the previous version (v3.4.0); these changes do not affect the trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedThe page now includes a glossary display option and updated metadata: the additions are 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision changed from v3.3.3 to v3.3.4; no study content or data were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Maryland location under a new Locations section and updated to revision v3.3.3; removed the Maryland Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

Stay in the know with updates to LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LMB-100 and Pembrolizumab in Mesothelioma Clinical Trial page.